

Antiinflammatory Mediator Lipoxin A₄ and Its Receptor in Synovitis of Patients with Rheumatoid Arthritis

ATSUSHI HASHIMOTO, IZUMI HAYASHI, YOUSUKE MURAKAMI, YOSHINORI SATO, HIDERO KITASATO, REIKO MATSUSHITA, NOBUKO IIZUKA, KEN URABE, MORITOSHI ITOMAN, SHUNSEI HIROHATA, and HIRAHITO ENDO

ABSTRACT. *Objective.* To evaluate the role of an antiinflammatory lipid mediator, lipoxin A₄ (LXA₄), in inflammatory arthritis, we measured the level of LXA₄ in synovial fluid and lipoxin A₄ receptor (ALX) expression in synovial tissues obtained from patients with rheumatoid arthritis (RA) and osteoarthritis (OA). *Methods.* Levels of LXA₄ and its analog (15-epi-LXA₄) in synovial fluid from 30 patients with RA and 15 patients with OA were measured by a specific ELISA. Reverse transcription-polymerase chain reaction (RT-PCR), real-time quantitative PCR, and *in situ* hybridization were performed to detect mRNA for ALX and 15-LOX, and LXA₄ synthetase, in synovial tissues from 20 patients with RA and 10 patients with OA. *Results.* Both LXA₄ and 15-epi-LXA₄ showed significantly higher levels in RA synovial fluid (10.34 ± 14.12 ng/ml for LXA₄) than OA synovial fluid (0.66 ± 0.77 ng/ml for LXA₄). Logarithmic concentration of LXA₄ was significantly correlated with that of leukotriene B₄ and prostaglandin E₂ in RA and OA synovial fluids. Expressions of ALX and 15-LOX mRNA were stronger in RA synovium than OA synovium. Expression of mRNA for interleukin 13 (IL-13), which induces 15-LOX, was significantly stronger in RA synovium than OA synovium. *Conclusion.* ALX is an important target of LXA₄ in synovial tissues of patients with RA. 15-LOX induced by IL-13 might regulate the production of LXA₄ to have an antiinflammatory effect against proinflammatory lipid mediators in inflamed joints. These findings could lead to the development of new therapy for inflammatory arthritis such as RA. (First Release Oct 1 2007; J Rheumatol 2007;34:2144–53)

Key Indexing Terms:

RHEUMATOID ARTHRITIS

LIPOXIN A₄

LIPOXIN

INFLAMMATION

From the Department of Rheumatology and Infectious Diseases and Department of Orthopedics, Kitasato University School of Medicine; Department of Microbiology, Kitasato University School of Allied Health Sciences, Kanagawa; Department of Pathophysiology, Nihon Pharmaceutical University, Saitama; Department of Pathology, Research Institute, International Medical Center of Japan; and Department of Medicine and Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan.

Supported in part by grants-in-aid from the Japanese Ministry of Education, Science, and Sports.

A. Hashimoto, MD, PhD, Lecturer; R. Matsushita, MD, Research Associate; N. Iizuka, MD, Research Associate; S. Hirohata, MD, Professor; H. Endo, MD, PhD, Associate Professor, Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine; I. Hayashi, Professor, Department of Pathophysiology, Nihon Pharmaceutical University; Y. Murakami, PhD, Research Resident, Department of Medicine and Rheumatology, Tokyo Medical and Dental University; Y. Sato, PhD, Research Fellow, Department of Pathology, Research Institute, International Medical Center of Japan; H. Kitasato, MD, Professor, Department of Microbiology, Kitasato University School of Allied Health Science; K. Urabe, MD, PhD, Associate Professor; M. Itoman, MD, Professor, Department of Orthopedics, Kitasato University School of Medicine.

Address reprint requests to Dr. A. Hashimoto, Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, 1-15-1 Kitasato, Sagamihara, Kanagawa 228-8555, Japan. E-mail: hashi@med.kitasato-u.ac.jp

Accepted for publication July 24, 2007.

Lipoxin A₄ (LXA₄) and its recently identified carbon-15 epimeric form, aspirin-triggered LXA₄ (15-epi-LXA₄), potently inhibit neutrophil activity and appear to serve as an endogenous “stop signal” that regulates excessive leukocyte trafficking and promotes resolution of inflammation¹. LXA₄ is synthesized by 5-lipoxygenase (LOX) and 12-LOX, or by 5-LOX and 15-LOX, via cell–cell interactions, while 15-epi-LXA₄ is produced by 5-LOX and acetylated prostaglandin H synthase-II after treatment with aspirin. Both 15-epi-LXA₄ and LXA₄ modulate leukocyte responses by interacting with the lipoxin A₄ receptor (ALX), which is a specific G-protein-coupled receptor². ALX was first identified in retinoic acid-differentiated HL-60 cells and then was cloned in mice, showing a high affinity to its endogenous lipid ligands (LXA₄ and 15-epi-LXA₄) as well as their stable bioactive analogs³. These compounds inhibit acute inflammation and reperfusion injury in both human cell models and murine models^{4–6}.

Rheumatoid arthritis (RA) is an autoimmune disease that is characterized by inflammatory polyarthritis and is associated with higher levels of proinflammatory arachidonic acid metabolites, such as leukotriene B₄ (LTB₄)⁷ and prostaglandin E₂ (PGE₂)⁸, in the synovial fluid than in that of patients with

osteoarthritis (OA). 5-LOX is expressed in synoviocytes⁹ and the synovial lining layer¹⁰ of patients with RA. Neutrophils in the synovial fluid¹¹ and peripheral blood¹² of patients with RA generate more LTB₄ via upregulated 5-LOX than the same cells from healthy individuals. PGE₂ induces 15-LOX in human neutrophils⁴, while 15-LOX was reported to be upregulated by interleukin 4 (IL-4)¹³ and IL-13¹⁴ in human monocytes. 15-LOX is a key enzyme of LXA₄ synthesis in inflammatory sites⁴. An earlier study showed that polymorphonuclear cells from patients with RA can release more lipoxins than those from healthy individuals¹⁵ and another exhibited the production of LXA₄ and 15-epi-LXA₄ by OA cartilage explants and ALX on OA chondrocytes^{16,17}. These studies suggest the relationship between the lipoxin system and the pathogenesis of RA and OA.

We investigated LXA₄ in synovial fluid, as well as the differences of ALX distribution and expression in synovial tissues between patients with RA and OA. Factors that may regulate the lipoxigenase pathway were also analyzed to assess the role of LXA₄ and its analogs in the pathogenesis of RA.

MATERIALS AND METHODS

Reagents. A mouse anti-5-LOX monoclonal antibody was purchased from Research Diagnostic Inc. (Flanders, NJ, USA). The anti-CD3 antibody, anti-CD4 antibody, anti-CD8 antibody, and anti-CD68 antibody, and anti-von Willebrand factor (vWF) antibody were all purchased from Dako (Carpinteria, CA, USA). A DIG-High Prime DNA Labeling and Detection Kit was obtained from Roche Diagnostics GmbH (Mannheim, Germany) and a Vectorstain ABC kit came from Vector Laboratories Inc. (Burlingame, CA, USA). Finally, 3,3'-diaminobenzidine (DAB) was obtained from Dojindo (Kumamoto, Japan) and a real-time quantitative polymerase chain reaction (PCR) kit (qPCR Mastermix for Sybr Green I) was purchased from Eurogentec (Seraing, Belgium).

Patients and samples. Synovial fluid specimens were obtained by arthrocentesis of the knee joint in 30 patients with RA and 15 with OA who consulted our institution (Table 1). Synovial tissue samples were obtained from 20 patients with RA and 10 with OA during orthopedic procedures for treatment at our institution. All patients with RA fulfilled the criteria of the American College of Rheumatology^{18,19}. OA was diagnosed according to clinical and radiological criteria. All patients gave informed consent for the use of their

Table 1. Clinical features of 45 patients with RA or OA used in the analysis of synovial fluid.

Feature	Diagnostic Group	
	RA	OA
Patients, n	30	15
Female:male	22:8	10:5
Age, yrs	57.23 ± 13.30	66.07 ± 12.20
CRP, mg/dl	3.037 ± 1.889	0.2256 ± 0.2308
Medication		
PSL, n (%)	27 (90)	0 (0)
PSL, mean ± SD (mg/day)	4.724 ± 2.658	0 ± 0
NSAID, n (%)	25 (83)	6 (40)
Aspirin, n (%)	4 (13)	1 (7)
Statin, n (%)	0 (0)	1 (7)

CRP: C-reactive protein; PSL: prednisolone; Statin: HMG-CoA reductase inhibitor; NSAID: nonsteroidal antiinflammatory drugs.

samples in research. In both groups, the clinical characteristics of the patients (sex, age, C-reactive protein, and therapy) were consistent with the diagnosis.

Samples were fixed in 4% paraformaldehyde within 6 h of resection and were embedded in OCT compound (Sakura Finetechnical Co., Ltd., Tokyo, Japan) after cooling in liquid nitrogen. Synovial fluid cells were obtained from the synovial fluid samples of patients with RA, and the percentages of neutrophils and mononuclear cells were evaluated by examination after Wright-Giemsa staining.

Measurement of LXA₄, LTB₄, and PGE₂ in synovial fluid. Synovial fluid samples were collected in polypropylene tubes and centrifuged at 1800 g for 10 min at 4°C. Cell-free supernatants of the fluid were stored at -70°C until use. LXA₄, LTB₄, and PGE₂ were separated from the supernatant by passage through octadecylsilyl silica columns (Sep-Pak C18, Waters Corp., Milford, MA, USA), followed by elution with methyl formate for LTB₄ and LXA₄, or with ethyl acetate containing 1% methanol for PGE₂. After evaporation to dryness, the residue was resuspended in the extraction buffer of each ELISA kit. The LXA₄ level in synovial fluid was determined with an ELISA kit (Neogen Corp., Lexington, KY, USA) according to the manufacturer's instructions, which was specific for LXA₄ and showed little cross-reactivity [LXA₄ 100%, lipoxin B₄ 1.0%, 15-hydroxyeicosatetraenoic acid (HETE) 0.1%, 5-HETE < 0.1%, and 12-HETE < 0.1%]. LTB₄ and PGE₂ were also measured in the same samples of synovial fluid with specific ELISA kits (LTB₄, Neogen Corp.; PGE₂, Cayman Chemical Co., Ann Arbor, MI, USA) according to the manufacturers' instructions.

Assessment of human LXA₄ receptor (ALX), 15-LOX, and IL-13 mRNA expression in synovial tissue by reverse transcription-PCR (RT-PCR) and real-time quantitative PCR. Total RNA was isolated from tissues or synovial fluid cells using the guanidium thiocyanate/phenol/chloroform method (Isogen Reagent Kit; Nippon Gene Co. Ltd., Toyama, Japan), and cDNA was synthesized from 2 µg of total RNA using RAV2 reverse transcriptase and Oligo (dT) primers (Takara Shuzo Co. Ltd., Shiga, Japan), as described²⁰.

The RT-PCR primers for human ALX (GenBank accession no. U81501) were 5'-CTG GCC CTG GCT TTT TCT TT-3' (sense: 219–241 bp) and 5'-GCC ACC TTC AGC CTC TCC TCA-3' (antisense: 581–601 bp), and the PCR product obtained with these primers was 383 bp in size²¹. The primers for human 5-LOX (GeneBank accession no. J03571) were 5'-CCG GCA CTG ACG ACT ACA TCT A-3' (sense: 81–102 bp) and 5'-CAC GGG GGT AAA TCC TTG TGG-3' (antisense: 514–533 bp), and the PCR product had a size of 453 bp⁹. The primers for human 15-LOX (GenBank accession no. M23892) were 5'-TGG CCG ACC TCG CTA TCA AAG ACT-3' (sense: 548–571 bp) and 5'-TGG GGG ATC CGT AGG CAA GAA AAG-3' (antisense: 991–1014 bp), and the PCR product had a size of 467 bp²². Human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (GenBank accession no. M33197) was used as the internal control, with 2 primers (5'-CAT CAT CTC TGC CCC CTC TG-3' and 5'-CCT GCT TCA CCA CCT TCT TG-3') yielding an expected PCR product of 437 bp²³.

Real-time quantitative PCR was performed to compare the expression of ALX, 15-LOX, IL-4, and IL-13 mRNA in the synovial tissue samples obtained from patients with RA and OA. cDNA from 20 patients with RA and 10 with OA was subjected to real-time quantitative PCR with the following primers: 5'-AAC CCC ATG CTT TAC GTC TTT GTG-3' (sense: 912–935 bp) and 5'-ATT GGC AGC CGT GTC ATT AGT TG-3' (antisense: 1012–1034 bp) for human ALX²¹, yielding a product of 123 bp; and 5'-ACC AGC CCC AGC AAG AGC ACA AG-3' (sense: 1081–1103 bp) and 5'-TTC AAG GGG TCT ACA TGG CAA CTG-3' (antisense: 1180–1203 bp) primers for human GAPDH (the control) yielding a product of 123 bp²³. The primers for human 15-LOX were 5'-CCG GAT TTT CTG GTG TGG TFC-3' (sense: 615–634 bp) and 5'-ACT AGG CGA GCA GGA AGG TGA-3' (antisense: 738–758 bp), and the PCR product had a size of 144 bp²². The primers for human IL-4 (GenBank accession no. BC066278) were 5'-TCT GTG CAC CGA GTT GAC C-3' (sense: 203–221 bp) and 5'-ACC CAG GCA GCG AGT GT-3' (antisense: 322–338 bp), and the product had a size of 136 bp²⁴. The primers for human IL-13 (GenBank accession no. NM_002188) were 5'-GGC CCT GAG CTC GGT GGA C-3' (sense: 679–697 bp) and 5'-CTA CAC

CCC TCC CCT GCC CTA-3' (antisense: 715–735 bp), with the product having a size of 57 bp²⁵.

Real-time PCR was done with a real-time quantitative PCR kit (qPCR Mastermix for Sybr Green I, Eurogentec) according to the manufacturer's protocol. Detection was performed by identifying the fluorescence of SYBR Green fluorescent dye (Eurogentec). Amplification was performed according to the standard protocol recommended by the manufacturer (2 min at 50°C, 10 min at 95°C, 40 cycles of 95°C for 15 s each, and annealing for 1 min at 56.9°C for ALX, 56.7°C for 15-LOX, 54.6°C for IL-4, and 55.5°C for IL-13). All samples were measured in duplicate. Analysis was carried out with an ABI Prism 7700 Sequence Detection System (Applied Biosystems Japan Ltd., Tokyo, Japan), and the calculated cycle threshold values (Ct) were exported to Microsoft Excel. For comparison between the sample groups, relative mRNA levels were subsequently normalized against values found in the patients with OA, which were defined as the baseline (reference value = 1).

In situ hybridization of ALX and 15-LOX in synovial tissue. PCR products of ALX and 15-LOX were purified from agarose gels using a StrataPrep PCR purification kit (Stratagene Cloning Systems, La Jolla, CA, USA) and were cloned using a Qiagen PCR cloning kit (Qiagen, Tokyo, Japan). Then the cDNA of ALX and 15-LOX were sequenced using an automated DNA sequencer (ABI Prism 310 Genetic Analyzer, Applied Biosystems).

Cryosections of synovium were mounted on silane-coated glass slides and fixed with 4% (w/v) paraformaldehyde. DIG-labeled antisense riboprobes for human ALX and 15-LOX were prepared by *in vitro* transcription of the pDrive Cloning Vector (Qiagen), which contained human ALX and 15-LOX cDNA²⁶, and a sense riboprobe prepared in the same way. The synovial sections were treated with 10 µg/ml proteinase K and hybridized with the labeled riboprobes in hybridization solution (Novagen, Madison, WI, USA) for 18 h at 50°C in moistened plastic boxes. After hybridization, the sections were treated with 20 µg/ml RNase A. After extensive washing, the binding of each probe was visualized with an alkaline-phosphate conjugated anti-DIG antibody in 5-bromo-4-chloro-3 indolyl-phosphate and 4-nitroblue tetrazolium chloride solution (Roche Diagnostics GmbH). Then the slides were counterstained with hematoxylin before examination.

Immunohistochemistry for 5-LOX and surface markers. Immunoperoxidase staining was done using a Vectorstain kit according to the manufacturer's protocol²⁷. Sections prepared from frozen samples were incubated in methanol containing 3% (v/v) H₂O₂ for 20 min to enhance endogenous peroxidase activity. Then the sections were preincubated in 0.3% (v/v) bovine serum albumin (Sigma-Aldrich Japan K.K., Tokyo, Japan) in phosphate-buffered saline (PBS) for 1 h, followed by incubation with diluted goat serum for 20 min. Subsequently, incubation was done in a humidified chamber for 1 h with an anti-5-LOX antibody (1:100; Research Diagnostics Inc.), anti-CD68 antibody, anti-CD3 antibody, anti-CD4 antibody, anti-CD8 antibody, anti-CD68 antibody, and anti-vWF antibody, or purified normal mouse IgG. After further washing with PBS, sections were incubated with biotinylated goat anti-mouse IgG (Dako) for 30 min, and washed again in PBS. Color was developed by treatment with DBA and the sections were counterstained with hematoxylin.

Statistical analysis. Results are expressed as the mean ± standard deviation. Mean values were compared by the Mann-Whitney test and $p < 0.05$ was considered to indicate a significant difference.

RESULTS

LXA₄ in synovial fluid of patients with RA and OA. The LXA₄ level in synovial fluid from affected joints of patients with RA or OA was measured by ELISA, and an increase of LXA₄ was detected in RA synovial fluid (Figure 1A). The mean concentration of LXA₄ in 30 RA synovial fluid samples was 10.34 ± 14.12 ng/ml, which was significantly greater than in the OA samples (0.66 ± 0.77 ng/ml; $p = 0.0023$). 15-epi-LXA₄ also showed a significantly higher concentration in RA synovial fluids (4.366 ± 4.376 ng/ml) than in OA synovial fluid (0.8553

± 1.692 ng/ml; $p < 0.0001$; Figure 1B). No significant correlation was found between LXA₄ or 15-epi-LXA₄ levels and patients' clinical features such as sex, age, serum C-reactive protein level, and medications except for prednisolone. As for prednisolone, most patients with RA took it and no patient with OA did. Only 4 patients with RA took aspirin and their 15-epi-LXA₄ levels in synovial fluids were not higher than those without aspirin (3.813 ± 6.192 with aspirin vs 4.451 ± 4.190 without aspirin). In patients with OA, a tendency of high LXA₄ and 15-epi-LXA₄ levels in synovial fluids was detected in patients treated without nonsteroidal antiinflammatory drugs (NSAID; containing aspirin) than those treated with NSAID (for LXA₄, 0.2971 ± 0.1687 with NSAID vs 0.9750 ± 0.9597 without NSAID; for 15-epi-LXA₄, 0.2871 ± 0.2310 with NSAID vs 1.353 ± 2.253 without NSAID), but this difference did not reach statistical significance ($p = 0.0820$ and 0.2239 , respectively). In patients with RA or OA, logarithmic concentrations of LXA₄ were significantly correlated with those of LTB₄ (Figure 1C; Pearson $r = 0.8464$, $p < 0.0001$) or PGE₂ (Figure 1D; Pearson $r = 0.7210$, $p < 0.0001$). Logarithmic concentrations of PGE₂ and LTB₄ were also significantly correlated (Figure 1E; Pearson $r = 0.7931$, $p < 0.0001$). Moreover, significant correlation between logarithmic concentrations of LXA₄ and 15-epi-LXA₄ was detected (Figure 1F; Pearson $r = 0.8119$, $p < 0.0001$).

ALX mRNA expression in synovial tissues of patients with RA or OA. We examined the expression of ALX mRNA in synovial tissues from 20 patients with RA and 10 with OA by RT-PCR and real-time quantitative PCR. Figure 2A shows that ALX mRNA signals were more strongly expressed in the synovial tissue of patients with RA compared to those with OA.

Real-time quantitative PCR revealed 10-fold higher expression of ALX mRNA in RA synovium (9.7 ± 14.48) than OA synovium (1.00 ± 1.01; $p = 0.0165$; Figure 2B).

To determine the distribution of ALX mRNA in the synovial tissues of patients with RA and OA, we performed *in situ* hybridization using DIG-labeled riboprobes. Macrophages were identified by positive staining with anti-CD68 antibody, while fibroblast-like cells were spindle-shaped cells that showed negative staining with anti-CD68 antibody and anti-CD3 antibody. Endothelial cells were identified using anti-vWF antibody. Strong signals for ALX mRNA were seen in macrophages and in a few fibroblast-like cells of the lining layer in patients with RA (Figure 3A, 3B), whereas these cells had faint signals in patients with OA (Figure 3C, 3D).

ALX mRNA expression by synovial fluid cells of patients with RA. Cells in the synovial fluid of 10 patients with RA were used to analyze ALX mRNA expression, revealing 84% ± 5% neutrophils and 16% ± 5% mononuclear cells. ALX mRNA was weakly expressed in cells from the RA synovial fluid by RT-PCR (Figure 2C).

5-LOX and 15-LOX mRNA expression in the synovial tissues of patients with RA or OA. 5-LOX and 15-LOX are the synthetases for LXA₄, and expression of their mRNA in the syn-




Figure 1. A. Concentration of LXA₄ in synovial fluid of patients with RA or OA. LXA₄ level was significantly higher in RA synovial fluid (10.34 ± 14.12 ng/ml) than OA synovial fluid (0.66 ± 0.77 ng/ml; $p = 0.0023$). B. Concentration of 15-epi-LXA₄ in RA and OA synovial fluids. 15-epi-LXA₄ level was also significantly higher in RA synovial fluid (2.60 ± 0.91 ng/ml) than in OA synovial fluid (0.94 ± 0.92 ng/ml; $p < 0.0001$). Results represent mean \pm SD ($n = 30$ RA, $n = 15$ OA). C. Double logarithmic plot shows a significant positive correlation between concentrations of LXA₄ and LTB₄ in RA and OA synovial fluids ($r = 0.8464$, $p < 0.0001$). D. Logarithmic concentrations of PGE₂ also correlated with those of LXA₄ ($r = 0.7210$, $p < 0.0001$). E. Logarithmic concentrations of PGE₂ correlated with those of LTB₄ ($r = 0.7931$, $p < 0.0001$). F. Logarithmic concentrations of LXA₄ correlated with those of 15-epi-LXA₄ ($r = 0.8119$, $p < 0.0001$).

Personal non-commercial use only. The Journal of Rheumatology Copyright © 2007. All rights reserved.




Figure 2. A. ALX mRNA expression in synovial tissues from 4 patients with RA and 2 with OA. ALX mRNA was detected by RT-PCR in all synovial samples, but its expression was relatively weak in OA tissues. B. Comparison of the expression of ALX mRNA between synovial tissues from patients with RA and OA. ALX mRNA expression was significantly stronger in RA synovium (9.74 ± 14.48) than in OA synovium (1.00 ± 1.01 , $p < 0.0165$). Results represent the mean \pm standard deviation ($n = 20$ for RA and $n = 10$ for OA). mRNA levels are shown relative to the mean value for OA, which was defined as 1. C. ALX mRNA expression in synovial fluid cells from 5 patients with RA. ALX mRNA expression in these cells was weak.

ovial tissues of patients with RA or OA was detected by RT-PCR. Figure 4A shows consistent strong expression of 5-LOX mRNA in RA and OA synovium. Compared with 5-LOX mRNA expression, 15-LOX mRNA expression was weaker in both RA and OA synovium. When 15-LOX mRNA expression in RA and OA synovium was compared by real-time quantitative PCR, its expression was stronger in the synovial tissues of patients with RA (3.01 ± 6.49) compared with those from patients with OA (1.00 ± 1.14), but this difference did not reach statistical significance ($p = 0.1659$; Figure 6B).


In situ hybridization of 15-LOX and immunohistochemical analysis of 5-LOX in synovial tissues of patients with RA. Localization of 5-LOX and 15-LOX in the synovial tissues of patients with RA was analyzed by *in situ* hybridization or immunohistochemistry, respectively. Intense signals for 15-LOX mRNA were detected in macrophages infiltrating RA synovium (Figure 5A, 5B). Immunostaining revealed 5-LOX expression in the synovial lining cells in samples from patients with RA (Figure 5C), as we reported¹⁰.

Quantitative analysis of IL-4 and IL-13 mRNA in synovial tissues of patients with RA and OA. 15-LOX is known to be induced by IL-4¹³ and IL-13¹⁴ in human monocytes. When the levels of IL-4 and IL-13 mRNA in synovial tissues from patients with RA and OA were assessed by real-time quantitative PCR, the tissues obtained from patients with RA showed significantly (4-fold) higher expression of IL-4 mRNA (4.16 ± 3.85) than those from patients with OA (1.00 ± 1.10 ; $p = 0.0060$; Figure 6A). Analysis of IL-13 mRNA also revealed higher expression in the synovial tissues of patients with RA (5.71 ± 7.88) compared with those from patients with OA (1.00 ± 0.69), but this difference was not significant ($p = 0.1659$; Figure 6B).


DISCUSSION

In our study, we detected an increase of LXA₄ and its analog (15-epi-LXA₄) in the synovial fluid as well as increased expression of the LXA₄ receptor (ALX) in synovial tissues of patients with RA compared with those from patients with OA. LXA₄ is an antiinflammatory mediator, and logarithmic concentration of LXA₄ in synovial fluid was positively correlated with that of LTB₄ and PGE₂, which were proinflammatory mediators. Sodin-Semrl, *et al*²⁸ reported that functioning LXA₄ receptors were expressed by cultured synovial fibroblasts, and suppressed IL-1 β -induced synovial cell activation. In activated synovial fibroblasts, LXA₄ inhibits the synthesis of inflammatory cytokines and matrix metalloproteinases, and also stimulates tissue inhibitor of metalloproteinase-1 production *in vitro*²⁸. These findings suggest that LXA₄ is involved in a negative feedback loop that opposes inflammatory cytokine-induced activation of synovial fibroblasts, although other ligands of ALX, for example annexin 1 (also called lipocortin 1) or serum amyloid A, can bind ALX and abrogate inflammation²⁹⁻³¹.


In vivo studies have recently demonstrated that LXA₄ significantly decreases inflammatory infiltrates and edema and has a more potent effect than equimolar concentrations of corticosteroids in mouse and guinea pig models of cutaneous inflammation³². Similarly, LXA₄ possesses antiinflammatory effects that may be involved in regulating pathophysiological processes related to the development of inflammatory arthritis such as RA. LXA₄ has a regulatory role in the cytokine network as demonstrated by suppression of tumor necrosis factor- α (TNF- α)-stimulated release of IL-1 β and macrophage inflammatory peptide-2, as well as superoxide production³³. Numerous types of cells, including neutrophils, monocytes, endothelial cells, and fibroblasts, express high affinity G-protein-coupled receptors (GPCR) for LXA₄ (ALX). Recent




A



B



C



D

Figure 3. *In situ* hybridization of ALX mRNA in synovial tissues from patients with RA or OA. **A.** Expression of ALX mRNA was seen in macrophages and fibroblast-like cells from the lining layer of RA synovium. **B.** Negative control: ALX sense probe staining of RA synovium. **C.** Macrophages in OA synovium are weakly positive for ALX mRNA. **D.** Negative control: ALX sense probe staining of OA synovium. **A-D:** Original magnification $\times 200$.




Figure 4. A. 5-LOX and 15-LOX mRNA expression in synovial tissues from 4 patients with RA and 2 with OA. 5-LOX and 15-LOX mRNA were detected by RT-PCR in all the samples, but 15-LOX expression was relatively weak compared with that of 5-LOX. B. Comparison of the expression of 15-LOX mRNA in synovial tissues from patients with RA and OA. ALX mRNA expression was stronger in RA synovium (3.01 ± 6.49) than in OA synovium (1.00 ± 1.14 , $p = 0.4679$). Results represent the mean \pm SD ($n = 20$ for RA and $n = 10$ for OA). mRNA levels are shown relative to the mean value for OA, which was defined as 1.

nomenclatures have clarified human ALX, which was at first recognized as formyl peptide receptor-like 1 (FPRL1)^{34,35}. FPRL1 is known to possess high DNA sequence homology (~70%) to human formyl peptide receptor (FPR), which is a low affinity receptor for LXA₄. FPRL2 is also one of the FPR family receptors, but LXA₄ has not been confirmed as a ligand for FPRL2. Although our primer sets for ALX cannot distinguish ALX from FPR or FPRL2, ALX is the only high affinity receptor for LXA₄. ALX transgenic mice showed diminished activation of the proinflammatory transcription factor nuclear factor-kappa B (NF-κB) in the local inflammatory response³⁶. Our data suggest that high levels of proinflammatory lipid mediators (PGE₂ and LTB₄) induce production of LXA₄ and 15-epi-LXA₄ for antiinflammation (Figure 1C, 1D, 1E, 1F)⁴.


Biosynthesis of leukotrienes is initiated by insertion of molecular oxygen at the carbon-5 position of arachidonic acid. Insertion of molecular oxygen at the carbon-5 and carbon-15 positions by 5-LOX and 15-LOX, respectively, results in the formation of lipoxins. This can occur through oxygenation of leukocyte-derived LTA₄ by platelet lipoxygenase through cell-cell interactions³⁷. Several reports have indicated that lipoxygenase can be found in synovial tissues from patients with RA.

Bonnet, *et al* described the expression of 5-LOX and 5-lipoxygenase-activating protein (FLAP) mRNA in cultured human synovial cells⁹ and our group has reported the presence of 5-LOX in the synovial lining layer¹⁰. In our study we demonstrated more highly expressed 15-LOX mRNA in synovial tissues from patients with RA than in those from patients with OA. The route of lipoxin formation depends on the cells and enzymes present and can be modulated by cytokines. IL-4¹³ and IL-13¹⁴, which are thought to be negative regulators of the inflammatory response, increase 15-LOX expression and activity as does PGE₂⁴, thereby enhancing LXA₄ formation. The generation of lipoxins by both proinflammatory and antiinflammatory mediators may lead to negative feedback


inhibition of the inflammatory response and thus protect the host from potentially deleterious neutrophil-induced responses. 15-LOX was more strongly expressed in the synovial lining of patients with RA than that of patients with OA (Figure 4B). In patients with RA, IL-13 mRNA was also detectable in synovial fluid mononuclear cells and synovial tissues, and the IL-13 level in synovial fluids was significantly higher than that reported for IL-4³⁸. 5-LOX was constitutively expressed in both RA and OA synovial tissues¹⁰. These data suggest that 15-LOX induced by IL-13 may be one of the regulators of the production of LXA₄ in inflamed joints. A wide distribution of LXA₄ levels in synovial fluids might depend on that of 15-LOX. Moreover, overexpression of leukotriene B₄ receptor 2 (BLT2) in synovial leukocytes of patients with RA¹⁰ could contribute to the upregulation of IL-13³⁹.

One of the pathways identified for LXA₄ biosynthesis involves platelet-neutrophil interactions³⁷. This pathway has been highlighted as a route of LXA₄ formation within the vasculature that involves 5-LOX in leukocytes and 12-LOX in platelets. There are numerous platelets in synovial joints, so platelets in synovial fluid might also be involved in LXA₄ formation.


In synovial fluids of patients with RA, 15-epi-LXA₄ was detected at about one-quarter the level of LXA₄. The concentration of 15-epi-LXA₄ in synovial fluids was around 10 times that in plasma (0.25 ± 0.63 ng/ml) in a report by Chiang, *et al*⁴⁰. Acetylation of cyclooxygenase-2 by aspirin could lead to transcellular biosynthesis of epi-lipoxin, the so-called aspirin-triggered lipoxins. Recently, in a randomized, placebo-controlled study of 8 weeks, a clinically relevant dose of aspirin was found to increase antiinflammatory 15-epi-LXA₄. Plasma 15-epi-LXA₄ levels at 8 weeks were significantly greater than those before aspirin treatment⁴⁰. In our study we were not able to detect the relation between aspirin taking and concentrations of 15-epi-LXA₄ in synovial fluids of patients with RA and OA. On the contrary, LXA₄ and 15-epi-LXA₄ levels were higher in OA patients without NSAID compared with those




A



B



C



D

Figure 5. In situ hybridization of 15-LOX mRNA and immunohistochemical analysis of 5-LOX in synovial tissues from patients with RA. A. Expression of 15-LOX mRNA is seen in macrophages from the lining layer (original magnification $\times 200$). B. Negative control: 15-LOX sense probe staining (original magnification $\times 100$). C. Synovial lining cells stained for 5-LOX (original magnification $\times 200$). D. Distribution of CD68-positive cells. Macrophages show staining by the anti-CD68 antibody (original magnification $\times 200$).




Figure 6. IL-4 and IL-13 mRNA expression in synovial tissues from patients with RA and OA. A. IL-4 mRNA expression was significantly stronger in RA synovium (4.16 ± 3.85) than in OA synovium (1.00 ± 1.10 , $p = 0.0060$). B. IL-13 mRNA expression was also stronger in RA synovium (5.71 ± 7.88) than in OA synovium (1.00 ± 0.69 , $p = 0.1659$). Results represent the mean \pm SD ($n = 20$ for RA and $n = 10$ for OA). mRNA levels are shown relative to the mean value for OA, which was defined as 1.

treated with NSAID, although 15-epi-LXA₄ levels in synovial fluid can differ from those in plasma. On the other hand HMG-CoA reductase inhibitor drugs, the so-called statins, were recently thought to generate 15-epi-LXA₄⁴¹, only one patient took statin in this study. Regulatory systems of lipoxins, especially 15-epi-LXA₄, remain to be elucidated.

Biosynthesis of lipid mediators has been observed to show a biphasic pattern during the inflammatory response. *In vivo* analysis of eicosanoid formation in a murine dorsal air-pouch model of inflammation has revealed a distinct time-dependent profile⁴². TNF-induced neutrophil accumulation within the dorsal pouch coincides with an increase of intradorsal PGE₂ levels. A persistent and marked increase of LXA₄ levels occurred, along with a reduction of neutrophil infiltration and PGE₂ production. Our synovial fluid analysis indicated that a patient with high levels of PGE₂ and LTB₄ had high levels of LXA₄ and 15-epi-LXA₄. Lee, *et al* reported that LXA₄ was detected in bronchoalveolar lavage fluid samples from 9 of 12 patients with lung disease and not detected in healthy control samples⁴³. Although another report demonstrated that bronchoalveolar lavage fluids in patients with scleroderma lung disease had low levels of LXA₄ and high levels of PGE₂ because of impaired stimulatory effect of PGE₂ on 15-LOX⁴⁴, our results support that LXA₄ is basically produced responding to PGE₂ in order to degrade the inflammation. It seems possible that PGE₂ induces a switch in lipid mediator synthesis from predominance of 5-LOX-yielding LTB₄ to predominance of 15-LOX-generating LXA₄, a response that would be paralleled by a reduction of neutrophil infiltration⁴. This leads to the proposal that biosynthesis of inflammatory lipid mediators is biphasic, with a role for eicosanoids in the initiation, progression, and termination of the inflammatory response. The initial phase is coupled to leukotriene biosynthesis, while subsequent prostaglandin formation is coupled to induction of lipoxygenase activity and lipoxin biosynthesis, promoting the resolution of inflammation.

Our study demonstrated that LXA₄ was synthesized in the

synovial tissues of patients with RA via a transcellular pathway, which might be regulated by IL-13-induced 15-LOX. LXA₄ and its analog can act as an antiinflammatory negative feedback system for proinflammatory mediators such as LTB₄ and PGE₂ that are involved in the pathogenesis of RA. Activation of lipoxin synthesis, for example by augmentation of 15-LOX, could be a potential new therapeutic approach for RA.

ACKNOWLEDGMENT

We thank Sachiko Kurihara and Terumi Mizuno for their skillful technical assistance.

REFERENCES

1. Takano T, Fiore S, Maddox JF, Brady HR, Petasis NA, Serhan CN. Aspirin-triggered 15-epi-lipoxin A₄ (LXA₄) and LXA₄ stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors. *J Exp Med* 1997;185:1693-704.
2. Serhan CN, Haeggstrom JZ, Leslie CC. Lipid mediator networks in cell signaling: update and impact of cytokines. *FASEB J* 1996;10:1147-58.
3. Fiore S, Romano M, Reardon EM, Serhan CN. Induction of functional lipoxin A₄ receptors in HL-60 cells. *Blood* 1993;81:3395-403.
4. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN. Lipid mediator class switching during acute inflammation: signals in resolution. *Nat Immunol* 2001;2:612-9.
5. Papiyanni A, Serhan CN, Brady HR. Lipoxin A₄ and B₄ inhibit leukotriene-stimulated interactions of human neutrophils and endothelial cells. *J Immunol* 1996;156:2264-72.
6. Chiang N, Gronert K, Clish CB, O'Brien JA, Freeman MW, Serhan CN. Leukotriene B₄ receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion. *J Clin Invest* 1999;104:309-16.
7. Klickstein LB, Shapleigh C, Goetzl EJ. Lipoxygenation of arachidonic acid as a source of polymorphonuclear leukocyte chemotactic factors in synovial fluid and tissue in rheumatoid arthritis and spondyloarthritis. *J Clin Invest* 1980;66:1166-70.
8. Trang LE, Granstrom E, Lovgren O. Levels of prostaglandins F₂ alpha and E₂ and thromboxane B₂ in joint fluid in rheumatoid arthritis. *Scand J Rheumatol* 1977;6:151-4.
9. Bonnet C, Bertin P, Cook-Moreau J, Chable-Rabinovitch H, Treves R, Rigaud M. Lipoxygenase products and expression of 5-lipoxygenase and 5-lipoxygenase-activating protein in human cultured synovial

- cells. Prostaglandins 1995;50:127-35.
10. Hashimoto A, Endo H, Hayashi I, et al. Differential expression of leukotriene B₄ receptor subtypes (BLT1 and BLT2) in human synovial tissues and synovial fluid leukocytes of patients with rheumatoid arthritis. *J Rheumatol* 2003;30:1712-8.
 11. Langholz E, Nielsen OH, Ahnfeldt-Ronne I, Elmgreen J. Arachidonic acid metabolism in neutrophil granulocytes obtained from synovial fluid in rheumatoid arthritis. *Scand J Rheumatol* 1990;19:387-91.
 12. Belch JJ, O'Dowd A, Ansell D, Sturrock RD. Leukotriene B₄ production by peripheral blood neutrophils in rheumatoid arthritis. *Scand J Rheumatol* 1989;18:213-9.
 13. Sigal E, Sloane DL, Conrad DJ. Human 15-lipoxygenase: induction by interleukin-4 and insights into positional specificity. *J Lipid Mediat* 1993;6:75-88.
 14. Nassar GM, Morrow JD, Roberts LJ 2nd, Lakkis FG, Badr KF. Induction of 15-lipoxygenase by interleukin-13 in human blood monocytes. *J Biol Chem* 1994;269:27631-4.
 15. Thomas E, Leroux JL, Blotman F, Chavis C. Conversion of endogenous arachidonic acid to 5,15-diHETE and lipoxins by polymorphonuclear cells from patients with rheumatoid arthritis. *Inflamm Res* 1995;44:121-4.
 16. Dave M, Attur M, Leung M, et al. Differential expression of lipoxin and lipoxin receptors in osteoarthritis cartilage: A functional genomic analysis [abstract]. *J Leukoc Biol Suppl* 2003;18.
 17. Amin A, Attur M, Dave M, Leung M, Abramson S. Functional and pharmacogenomic analysis of lipid mediators in human osteoarthritis-affected cartilage [abstract]. *J Leukoc Biol Suppl* 2003;31.
 18. Ropes MW, Bennett GA, Cobb S, Jacox R, Jessar RA. Revision of diagnostic criteria for rheumatoid arthritis. *Bull Rheum Dis* 1958;9:175-6.
 19. Arnett FC, Edworthy SM, Bloch DA, et al. The Arthritis and Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 1988;31:315-24.
 20. Kimmel AR, Berger SR. Preparation of cDNA and the generation of cDNA libraries: overview. *Methods Enzymol* 1987;152:307-16.
 21. Maddox JF, Hachicha M, Takano T, Petasis NA, Fokin VV, Serhan CN. Lipoxin A₄ stable analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-protein-linked lipoxin A₄ receptor. *J Biol Chem* 1997;272:6972-8.
 22. Sigal E, Craik CS, Highland E, et al. Molecular cloning and primary structure of human 15-lipoxygenase. *Biochem Biophys Res Commun* 1988;157:457-64.
 23. Tokunaga K, Nakamura Y, Sakata K, et al. Enhanced expression of a glyceraldehyde-3-phosphate dehydrogenase gene in human lung cancers. *Cancer Res* 1987;47:5616-9.
 24. Strausberg RL, Feingold EA, Grouse LH, et al. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. *Proc Natl Acad Sci USA* 2002;99:16899-903.
 25. Minty AJ, Chalou P, Derocq JM, et al. Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. *Nature* 1993;362:248-50.
 26. Kurihara Y, Endo H, Akahoshi T, Kondo H. Up-regulation of prostaglandin E receptor EP2 and EP4 subtypes in rat synovial tissues with adjuvant arthritis. *Clin Exp Immunol* 2001;123:323-30.
 27. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. *J Histochem Cytochem* 1981;29:577-80.
 28. Sodin-Semrl S, Taddeo B, Tseng D, Varga J, Fiore S. Lipoxin A₄ inhibits IL-1 beta-induced IL-6, IL-8, and matrix metalloproteinase-3 production in human synovial fibroblasts and enhances synthesis of tissue inhibitors of metalloproteinases. *J Immunol* 2000;164:2660-6.
 29. Hayhoe RP, Kamal AM, Solito E, Flower RJ, Cooper D, Perretti M. Annexin 1 and its bioactive peptide inhibit neutrophil-endothelium interactions under flow: indication of distinct receptor involvement. *Blood* 2006;107:2123-30.
 30. O'Hara R, Murphy EP, Whitehead AS, FitzGerald O, Bresnihan B. Local expression of the serum amyloid A and formyl peptide receptor-like 1 genes in synovial tissue is associated with matrix metalloproteinase production in patients with inflammatory arthritis. *Arthritis Rheum* 2004;50:1788-99.
 31. Fiore S, Antico G, Aloman M, Sodin-Semrl S. Lipoxin A4 biology in the human synovium. Role of the ALX signaling pathways in modulation of inflammatory arthritis. *Prostaglandins Leukot Essent Fatty Acids* 2005;73:189-96.
 32. Schottelius AJ, Giesen C, Asadullah K, et al. An aspirin-triggered lipoxin A₄ stable analog displays a unique topical anti-inflammatory profile. *J Immunol* 2002;169:7063-70.
 33. Hachicha M, Pouliot M, Petasis NA, Serhan CN. Lipoxin (LX) A₄ and aspirin-triggered 15-epi-LXA₄ inhibit tumor necrosis factor 1-alpha-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis. *J Exp Med* 1999;189:1923-30.
 34. Brink C, Dahlen SE, Drazen J, et al. International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors. *Pharmacol Rev* 2003;55:195-227.
 35. Chiang N, Serhan CN, Dahlen SE, et al. The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. *Pharmacol Rev* 2006;58:463-87.
 36. Devchand PR, Arita M, Hong S, et al. Human ALX receptor regulates neutrophil recruitment in transgenic mice: roles in inflammation and host defense. *FASEB J* 2003;17:652-9.
 37. Serhan CN. Lipoxins and novel aspirin-triggered 15-epi-lipoxins (ATL): a jungle of cell-cell interactions or a therapeutic opportunity? *Prostaglandins* 1997;53:107-37.
 38. Isomaki P, Luukkainen R, Toivanen P, Punnonen J. The presence of interleukin-13 in rheumatoid synovium and its antiinflammatory effects on synovial fluid macrophages from patients with rheumatoid arthritis. *Arthritis Rheum* 1996;39:1693-702.
 39. Miyahara N, Takeda K, Miyahara S, et al. Requirement for leukotriene B₄ receptor 1 in allergen-induced airway hyperresponsiveness. *Am J Respir Crit Care Med* 2005;172:161-7.
 40. Chiang N, Bermudez EA, Ridker PM, Hurwitz S, Serhan CN. Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. *Proc Natl Acad Sci U S A*. 2004;101:15178-83.
 41. Birnbaum Y, Ye Y, Lin Y, et al. Augmentation of myocardial production of 15-epi-lipoxin-a4 by pioglitazone and atorvastatin in the rat. *Circulation* 2006;114:929-35.
 42. Pouliot M, Clish CB, Petasis NA, Van Dyke TE, Serhan CN. Lipoxin A (4) analogues inhibit leukocyte recruitment to *Porphyromonas gingivalis*: a role for cyclooxygenase-2 and lipoxins in periodontal disease. *Biochemistry* 2000;39:4761-8.
 43. Lee TH, Crea AE, Gant V, et al. Identification of lipoxin A4 and its relationship to the sulfidopeptide leukotrienes C4, D4, and E4 in the bronchoalveolar lavage fluids obtained from patients with selected pulmonary diseases. *Am Rev Respir Dis* 1990;141:1453-8.
 44. Kowal-Bielecka O, Kowal K, Distler O, et al. Cyclooxygenase- and lipoxygenase-derived eicosanoids in bronchoalveolar lavage fluid from patients with scleroderma lung disease: an imbalance between proinflammatory and antiinflammatory lipid mediators. *Arthritis Rheum* 2005;52:3783-91.